TCR gene-engineered cell therapy for solid tumors

Tan, Elaine; Gakhar, Neel; Kirtane, Kedar

doi:10.1016/j.beha.2021.101285

Cited by 16 publications

(14 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell receptor-engineered T-cell (TCR-T) therapy has the advantage of targeting potentially any antigen, not only those expressed on the surface of cells, such as with CAR-T-cells. Recent clinical studies on TCR-T showed meaningful results in solid tumor patients [ 191 , 192 , 193 ], with New York esophageal squamous cell carcinoma-1 (NY-ESO-1) being the most frequently targeted, with a relevant clinical response rate in metastatic melanoma and in metastatic synovial sarcoma patients [ 194 , 195 , 196 ].…”

Section: Tcr and Cancermentioning

confidence: 99%

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

Mazzotti

Gaimari

Bravaccini

et al. 2022

IJMS

View full text Add to dashboard Cite

The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and biological agents shape the development and behavior of this complex and diffuse system. Many pathological conditions depend on how our immune system responds or does not respond to a pathogen or a disease or on how the regulation of immunity is altered by the disease itself. T-cells are important players in adaptive immunity and, together with B-cells, define specificity and monitor the internal and external signals that our organism perceives through its specific receptors, TCRs and BCRs, respectively. Today, high-throughput sequencing (HTS) applied to the TCR repertoire has opened a window of opportunity to disclose T-cell repertoire development and behavior down to the clonal level. Although TCR repertoire sequencing is easily accessible today, it is important to deeply understand the available technologies for choosing the best fit for the specific experimental needs and questions. Here, we provide an updated overview of TCR repertoire sequencing strategies, providers and applications to infectious diseases and cancer to guide researchers’ choice through the multitude of available options. The possibility of extending the TCR repertoire to HLA characterization will be of pivotal importance in the near future to understand how specific HLA genes shape T-cell responses in different pathological contexts and will add a level of comprehension that was unthinkable just a few years ago.

show abstract

Section: Tcr and Cancermentioning

confidence: 99%

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

Mazzotti

Gaimari

Bravaccini

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…In summary, TCR-T cell therapy has shown good potential in both preclinical and clinical studies (8,35,102,107,(114)(115)(116). However, clinical trials evaluating TCR-T for CRC are still in their early phases, and the safety and efficacy of these therapies still face many challenges (43).…”

Section: Tcr-t Therapymentioning

confidence: 99%

“…Such antigens may include melanoma antigen recognized by T cells 1 (MART-1), gp100, CEA, New York esophageal squamous cell carcinoma-1 (NY-ESO-1), melanoma-associated antigen A3 (MAGE-A3), melanoma-associated antigen A4 (MAGE-A4), HER2, and CD19 ( 106 ). Due to their high specificities and strong immunogenicities, neoantigens (neoAgs) have been considered the ideal targets for antitumor immunotherapy ( 107 ).…”

Section: Tcr-t Therapymentioning

confidence: 99%

Advances in adoptive cellular therapy for colorectal cancer: a narrative review

Yi¹,

Hu²

2022

Ann Transl Med

View full text Add to dashboard Cite

Background and Objective: In recent years, adoptive cell therapy (ACT) has shown great potential in antitumor treatment. To significantly improve the clinical efficacy of ACT against solid tumors, we may need to carefully study the latest developments in ACT. As one of the most common malignancies, colorectal cancer (CRC) is a major risk to human health and has become a significant burden on global healthcare systems. This article reviews the recent advances in the treatment of CRC with ACT.Methods: We searched PubMed for articles related to ACT for CRC published as of August 31, 2022, and retrieved relevant clinical trial information on the National Institutes of Health ClinicalTrials.gov website.Based on search results, comprehensive and systematic review is made.

show abstract

“…However, in the case of CAR-T treatment, CAR-T cells can migrate throughout the body via the blood, which is efficient for spreading cancer-like disorders [2,10,[23][24]. Besides, CAR-T cells can live in the human body for more than ten years, reducing the likelihood of cancer recurrence.…”

Section: Surgical Treatmentmentioning

confidence: 99%

“…However, CIK and other non-specific activated lymphocytes lack tumor-specific response-ability. In this situation, scientists have started to introduce T cell receptor (TCR) or CAR genes that recognize tumor antigens into lymphocytes through genetic modification to make them TCR genemodified T lymphocytes (TCR-T) or CAR-T cells with tumor antigen targeting recognition ability [22,24,25].…”

Section: Tumor-infiltrating Lymphocyte (Til) and T Cell Receptor (Tcr)mentioning

confidence: 99%

CAR-T Therapy: A Promising Cancer Treatment

Fang¹,

Liu²,

Song³

2022

HSET

View full text Add to dashboard Cite

CAR-T therapy is a new clinical treatment option. It is the focus of an increasing number of researches, all of which suggested that it has a beneficial therapeutic effect on a variety of diseases, especially blood cancer. In this paper, clinic applications of CAR-T therapy for many diseases are listed, including B-cell acute lymphoblastic leukemia, Hepatitis B, and Human Immunodeficiency Virus. The differences between CAR-T therapy and other cancer treatments like tumor-infiltrating lymphocyte and T cell receptor therapy were discussed, standard biological medicines, and antibody-mediated anti-cancer drugs. The study also looks at the limitations and side-effects of CAR-T therapy, such as toxicity, and missing the target. The disadvantages, constraints, and options for improvement were also discussed in the paper. To summarize, CAR-T therapy has a good therapeutic function on some illnesses, although it is still in the experimental stage and is not commonly used in the clinic. In the near future, CAR-T therapy is likely to be used in a rising range of therapeutic therapies. In general, this paper can help get a better knowledge of CAR-T treatment, as well as a more exact comprehension of its future evolution.

show abstract

TCR gene-engineered cell therapy for solid tumors

Cited by 16 publications

References 59 publications

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer

Advances in adoptive cellular therapy for colorectal cancer: a narrative review

CAR-T Therapy: A Promising Cancer Treatment

Contact Info

Product

Resources

About